Date of Abstract presentation11th December 2023IndicationsRelapsed or Refractory (R/R) B-Cell MalignanciesAbstract Number4401Abstract typePoster
The preliminary results from this ongoing clinical trial, unveiled at the ASH 2023 conference, demonstrated that, among the efficacy evaluable patients (n=28), BGB-16673 produced an overall response rate (ORR) of 57%. Moreover, the outcomes encompassed a diverse spectrum, including one complete response (CR), 13 partial responses (PRs), 1 PR with lymphocytosis (PR-L), and one minor response (MR). Additionally, five patients attained stable disease (SD), while five experienced progressive disease (PD). Two patients opted to...
